V. Menon

An Open-Label, Single-Period, Two-Stage, Single Oral Dose Pharmacokinetic Study of Remogliflozin Etabonate Tablet 100 and 250 mg in Healthy Asian Indian Male Subjects Under Fasting and Fed Conditions

G. Gudi, S. Joshi, Waseem Siddique, 2019, Clinical Pharmacokinetics.

ISB 1442, a First-in-Class CD38 and CD47 Bispecific Antibody Innate Cell Modulator for the Treatment of Relapsed Refractory Multiple Myeloma

G. Gudi, M. Panagopoulou, C. Grandclément, 2021, Blood.

Pre-clinical characterization of ISB 1342, a CD38xCD3 T-cell engager for relapsed/refractory multiple myeloma.

Ankit Srivastava, G. Gudi, G. Borthakur, 2023, Blood.

Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

G. Gudi, C. Huff, M. Mohty, 2022, Blood.

Ketorolac Tromethamine Transdermal Gel: Development, In Vitro and In Vivo Evaluation

R. Mullangi, V. Venkateswarlu, R. Dubey, 2009, Journal of pain & palliative care pharmacotherapy.